Company Monitoring Page for Roche

latest headlines for company on cafepharma

AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
Wed, 03/22/23 - 10:03 am
Tags:
AACR, Moderna Therapeutics, Allogene, AstraZeneca, Merck, Roche, Novartis, Eli Lilly, Innovent, Springworks, Biogene, Relay Therapeutics, Vivace Therapeutics
FDA adcomm votes 11-2 to expand Roche's Polivy label in DLBCL
Endpoints
Thu, 03/9/23 - 10:21 pm
Tags:
Roche, FDA, Polivy, DLBCL
FDA advisers question efficacy of Roche’s Polivy in first line LBCL
BioSpace
Wed, 03/8/23 - 11:30 am
Tags:
Roche, Genentech, Polivy, LBCL, large B-cell lymphoma
Swiss biotech Noema raises $112m for Roche castoffs
Pharmaphorum
Tue, 03/7/23 - 11:19 am
Tags:
Noema, Roche, neurological disorders, funding
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Fri, 03/3/23 - 12:01 pm
Tags:
Roche, Exelixis, renal cell carcinoma, Tecentriq, Cabometyx, clinical trials
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Wed, 03/1/23 - 07:08 pm
Tags:
Roche, Genentech, patents, MS, multiple sclerosis, legal, Tysabri
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
Tags:
FDA, Acadia Pharmaceuticals, Apellis Pharmaceuticals, AstraZeneca, Biogen, Biomarin, Cidara Therapeutics, Emergent BioSolutions, GSK, Incyte, Ionis Pharmaceuticals, Melinta Therapeutics, Mundipharma, Novartis, Pfizer, Pharming, Regeneron, Roche, vaccines, RSV, ALS, COVID-19
New Report Reveals Pharmaceutical Industry Social Media Pioneers
LBB Online
Fri, 02/24/23 - 08:52 am
Tags:
Ogilvy Health, social media, Bristol Myers Squibb, Boehringer Ingelheim, Roche
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Endpoints
Thu, 02/23/23 - 04:30 pm
Tags:
Roche, Gavreto, Blueprint Medicines, cancer
Genentech's California biologics facility will support launches in cancer, neuroscience and more: exec
Fierce Pharma
Tue, 02/21/23 - 04:46 pm
Tags:
Genentech, California, Roche, biologics, drug manufacturing
Novartis, Roche avoid $475M antitrust fine in French appeals court
Fierce Pharma
Mon, 02/20/23 - 12:57 pm
Tags:
Novartis, Roche, antitrust, Lucentis
Bayer's 3 business units 'perfectly positioned,' trade union says in resistance to potential breakup
Fierce Pharma
Mon, 02/13/23 - 09:56 pm
Tags:
Bayer, Roche, Werner Baumann, restructuring
Genentech to start construction on a new manufacturing facility in California
Endpoints
Sun, 02/12/23 - 07:40 pm
Tags:
Genentech, Roche, drug manufacturing, California
Trials cue up new use for Roche's eye disease drug Vabysmo
Pharmaphorum
Fri, 02/10/23 - 10:23 am
Tags:
Roche, Vabysmo, clinical trials, retinal vein occlusion
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
BioSpace
Thu, 02/9/23 - 10:53 am
Tags:
Roche, Janssen, JNJ, companion diagnostics, diagnostics
Bayer taps Roche's Bill Anderson to lead pharma giant as CEO
Endpoints
Wed, 02/8/23 - 10:59 pm
Tags:
Bayer, Bill Anderson, Roche, Pharma CEOs
Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3
Fierce Biotech
Tue, 02/7/23 - 11:04 am
Tags:
Roche, PNH, AstraZeneca, crovalimab, Soliris
mRNA vaccines: Four major clinical trial readouts to watch in 2023
Clinical Trials Arena
Thu, 02/2/23 - 10:57 pm
Tags:
MRNA, clinical trials, vaccines, Moderna Therapeutics, Pfizer, Flu, Roche, BioNTech, melnaoma, genital herpes
Roche Abandons AKT Prostate Cancer Asset
BioSpace
Thu, 02/2/23 - 10:52 am
Tags:
Roche, AKT inhibitors, Ipatasertib, clinical trials, castration-resistant prostate cancer, prostate cancer
Incoming Roche CEO builds out his top team, tapping Genentech vet to lead pharma division
Endpoints
Thu, 02/2/23 - 10:30 am
Tags:
Roche, Teresa Graham, Thomas Schinecker, Pharma CEOs

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.